Chemomab Therapeutics Ltd Stock Market Value
| CMMB Stock | USD 1.80 0.08 4.26% |
| Symbol | Chemomab |
Chemomab Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemomab Therapeutics. If investors know Chemomab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chemomab Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Chemomab Therapeutics is measured differently than its book value, which is the value of Chemomab that is recorded on the company's balance sheet. Investors also form their own opinion of Chemomab Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Chemomab Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemomab Therapeutics' market value can be influenced by many factors that don't directly affect Chemomab Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemomab Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Chemomab Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemomab Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Chemomab Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Chemomab Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Chemomab Therapeutics.
| 11/29/2025 |
| 12/29/2025 |
If you would invest 0.00 in Chemomab Therapeutics on November 29, 2025 and sell it all today you would earn a total of 0.00 from holding Chemomab Therapeutics Ltd or generate 0.0% return on investment in Chemomab Therapeutics over 30 days. Chemomab Therapeutics is related to or competes with Kazia Therapeutics, Theriva Biologics, Elevai Labs,, Can Fite, Biovie, XORTX Therapeutics, and InMed Pharmaceuticals. Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of i... More
Chemomab Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Chemomab Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Chemomab Therapeutics Ltd upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.10) | |||
| Maximum Drawdown | 31.6 | |||
| Value At Risk | (7.69) | |||
| Potential Upside | 5.6 |
Chemomab Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Chemomab Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Chemomab Therapeutics' standard deviation. In reality, there are many statistical measures that can use Chemomab Therapeutics historical prices to predict the future Chemomab Therapeutics' volatility.| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.56) | |||
| Total Risk Alpha | (0.98) | |||
| Treynor Ratio | (0.29) |
Chemomab Therapeutics Backtested Returns
Chemomab Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0941, which signifies that the company had a -0.0941 % return per unit of standard deviation over the last 3 months. Chemomab Therapeutics Ltd exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Chemomab Therapeutics' mean deviation of 3.58, and Risk Adjusted Performance of (0.05) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.52, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Chemomab Therapeutics will likely underperform. At this point, Chemomab Therapeutics has a negative expected return of -0.48%. Please make sure to confirm Chemomab Therapeutics' potential upside, day median price, and the relationship between the treynor ratio and accumulation distribution , to decide if Chemomab Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.57 |
Modest predictability
Chemomab Therapeutics Ltd has modest predictability. Overlapping area represents the amount of predictability between Chemomab Therapeutics time series from 29th of November 2025 to 14th of December 2025 and 14th of December 2025 to 29th of December 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Chemomab Therapeutics price movement. The serial correlation of 0.57 indicates that roughly 57.0% of current Chemomab Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.57 | |
| Spearman Rank Test | 0.43 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Chemomab Therapeutics lagged returns against current returns
Autocorrelation, which is Chemomab Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Chemomab Therapeutics' stock expected returns. We can calculate the autocorrelation of Chemomab Therapeutics returns to help us make a trade decision. For example, suppose you find that Chemomab Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Chemomab Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Chemomab Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Chemomab Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Chemomab Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Chemomab Therapeutics Lagged Returns
When evaluating Chemomab Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Chemomab Therapeutics stock have on its future price. Chemomab Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Chemomab Therapeutics autocorrelation shows the relationship between Chemomab Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Chemomab Therapeutics Ltd.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Chemomab Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Chemomab Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Chemomab Therapeutics Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Chemomab Therapeutics Ltd Stock:Check out Chemomab Therapeutics Correlation, Chemomab Therapeutics Volatility and Chemomab Therapeutics Alpha and Beta module to complement your research on Chemomab Therapeutics. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Chemomab Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.